Status:
COMPLETED
Irinotecan Study For Cervical Cancer
Lead Sponsor:
Pfizer
Conditions:
Uterine Cervical Neoplasms
Eligibility:
FEMALE
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to evaluate the efficacy and safety of Irinotecan plus cisplatin as first-line chemotherapy for advanced or recurrent cervical cancer
Eligibility Criteria
Inclusion
- Histologically documented, advanced or recurrent squamous cell carcinoma of uterine cervix. Patients may have received concurrent (with radiotherapy) or (neo)adjuvant (before or after local treatment) chemotherapy for primary tumor providing that at least 6 months have passed from the completion of previous therapy and the diagnosis of recurrent disease was documented
- Having measurable lesion(s), without previous radiation therapy.
Exclusion
- Patients had ever received primary chemotherapy for cervical cancer other than mentioned previously (in the inclusion criteria).
- Patients ever received cisplatin with total dose \> 300 mg/m2 and received radiotherapy or local treatment delivered to the target lesion.
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00136955
Start Date
June 1 2004
End Date
May 1 2008
Last Update
June 19 2015
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Kwei-Shan County, TaoYuan,, Taiwan, Taiwan
2
Pfizer Investigational Site
Taichung, Taiwan, Taiwan
3
Pfizer Investigational Site
Taipei, Taiwan, Taiwan, 112
4
Pfizer Investigational Site
Kaoshiung, Taiwan, 813